Visualitza per autor "Kim, Hye Ryun"
Ara mostrant els elements 1-3 d 3
-
Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial
Camidge, D. Ross; Ahn, Myung-Ju; Yang, James C. H.; Han, Ji-Youn; Hochmair, Maximilian J.; Felip Font, Enriqueta; Kim, Hye Ryun (American Society of Clinical Oncology, 2020-11-01) -
Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial
Camidge, D. Ross; Ahn, Myung-Ju; Yang, James C. H.; Han, Ji-Youn; Hochmair, Maximilian J.; Felip Font, Enriqueta; Kim, Hye Ryun (Elsevier, 2021-12-01) -
Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC
Kim, Hye Ryun; Gottfried, Maya; Peters, Solange; Csoszi, Tibor; Awad, Mark; NAVARRO, ALEJANDRO (Elsevier, 2023-11)